Recently, research in our laboratory has revealed that miR-520b inhibits the migration of breast cancer cells by targeting interleukin-8 (IL-8) and hepatitis B X-interacting protein (HBXIP) [11]. Here, CXCL8 is linked to breast carcinoma.